title: Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
abstract: High profits and high drug costs have brought increased scrutiny of the pharmaceutical industry over the issue of whether the drugs they produce are worth the costs. I examine several related complaints, including the proliferation of me-too drugs and product reformulations, which some argue have little value relative to their cost; the baseless promotion of newer drug classes as more effective than existing, less expensive drugs; legal strategies to extend market exclusivity that result in high brand-name drug prices for an extended period of time; and large promotional expenditures that result in higher prices.
authors: Harvard Medical School, Boston, Massachusetts, USA. huskamp@hcp.med.harvard.edu
authors: Haiden A
authors: HA
authors: Huskamp